A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailprint

March 6, 2009

Call for a Coordinated Cure Effort

Several top researchers, a noted AIDS activist and two industry scientists have called for a collaborative and coordinated effort to find ways to eradicate HIV from the body, according to an article they’ve written in the March 6 issue of Science and reported on by aidsmap. They claim that eradication will be extremely difficult to achieve, but that failing to shoot for it is unacceptable.

The group responsible for the article, led by Douglas Richman, MD, director of the Center for AIDS Research at the University of California in San Diego, points out that although funding is available through the National Institutes of Health (NIH) for individual researchers working on specific aspects of eradication, there is no coordinated effort, as has been instituted in recent years in the search for an effective HIV vaccine.

One of the key eradication challenges is the incomplete knowledge about how HIV manages to persist despite being almost completely shut down by the most potent antiretroviral (ARV) drugs. Robert Siliciano, MD, from Johns Hopkins University in Baltimore, gave the opening plenary lecture at the recent 16th Conference on Retroviruses and Opportunistic Infections in Montreal on this topic.

Siliciano explained that a tiny—one in a million—subset of latent infected CD4 cells manages to continue producing HIV at extremely low levels in people on ARV therapy. Moreover, there may be other cells, called macrophages, that continue to produce low levels of virus as well. Scientists are not entirely clear how these cells manage to evade the HIV-blocking effects of ARV therapy.

Another scientist who coauthored the Science article, David Margolis, MD, from the University of North Carolina in Chapel Hill, has long sought drugs that could activate, or “wake up,” these latent cells so that they would be accessible to ARV treatment. The challenge, however, is how to activate only those cells infected with HIV, and not uninfected cells. Broad level activation of all resting cells would be fatal.

The article’s authors argue that only a collaborative effort involving the government, the pharmaceutical industry and private donors has the potential to overcome the challenges involved in eradication research. They are advocating for what they call a “collaboratory,” where the various stakeholders share both data and resources and work together in tackling the vital scientific questions that remain unanswered.

Cure-based research is a cause that was championed by longtime AIDS activist Martin Delaney, who died six weeks ago from liver cancer. Delaney coauthored the article, which was dedicated to his memory.

Search: Cure, HIV, Douglas Richman, David Margolis, Martin Delaney, Science, eradication


Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    alphatango
    Phoenix
    Arizona


    newlife202
    JOLIET
    Illinois


    FoxyFresh57
    Bronx
    New York


    jdog46948
    Detroit
    Michigan
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.